title: [Hepatitis B reactivation in an HbsAg-negative/anti-HBc-positive patient with B-cell non-Hodgkin lymphoma receiving chemotherapy with rituximab].
abstract: Reactivation of hepatitis B virus infection in patients with resolved infection is rare and is usually associated with immunosuppressive therapy. Morbidity and mortality are high. Some cases of hepatitis B reactivation associated with the use of rituximab have previously been published. We present the case of a patient with B-cell non-Hodgkin lymphoma receiving combination chemotherapy with rituximab who showed hepatitis B reactivation followed by liver failure. The most recent literature on this topic is reviewed and discussed.
authors.affiliation: Sección de Aparato Digestivo, Hospital Morales Meseguer, Murcia, España. emunozb@telefonica.net
authors.forename: Eduardo
authors.initials: E
authors.lastname: Muñoz Bertrán
authors.forename: Elena
authors.initials: E
authors.lastname: Pérez Ceballos
authors.forename: Rosa
authors.initials: R
authors.lastname: Gómez Espín
authors.forename: Isabel
authors.initials: I
authors.lastname: Ortega González
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived; D000918:Antibody Specificity; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D015897:Comorbidity; D003520:Cyclophosphamide / Q000008:administration & dosage; D017809:Fatal Outcome; D006510:Hepatitis B Antibodies / Q000097:blood* / Q000276:immunology; D006512:Hepatitis B Core Antigens / Q000276:immunology*; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000502:physiology*; D019694:Hepatitis B, Chronic / Q000150:complications* / Q000188:drug therapy / Q000821:virology; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects*; D007167:Immunotherapy / Q000009:adverse effects*; D017093:Liver Failure / Q000209:etiology; D018442:Lymphoma, B-Cell, Marginal Zone / Q000150:complications* / Q000188:drug therapy; D008297:Male; D063065:Organophosphonates / Q000627:therapeutic use; D011241:Prednisone / Q000008:administration & dosage; D012008:Recurrence; D000069283:Rituximab; D000068698:Tenofovir; D014750:Vincristine / Q000008:administration & dosage; D014775:Virus Activation / Q000187:drug effects* / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D006510:Hepatitis B Antibodies; D006512:Hepatitis B Core Antigens; D006514:Hepatitis B Surface Antigens; D007155:Immunologic Factors; D063065:Organophosphonates; D000069283:Rituximab; D014750:Vincristine; D003520:Cyclophosphamide; D000068698:Tenofovir; D000225:Adenine; D011241:Prednisone